OBJECTIVE: To evaluate efficacy and safety of aggressive correction of hypophosphatemia with intravenous potassium phosphate in the ICU. DESIGN AND SETTING: Randomized interventional prospective study in the medical and surgical ICU of a tertiary university hospital. PATIENTS: Critically ill patients with hypophosphatemia between June and November 1998. MEASUREMENTS AND RESULTS:Patients with moderate hypophosphatemia (<0.65 and >0.40 mmol/l; n=37) were randomized into two groups: group 1 received 30 mmol potassium phosphate intravenously in 50 ml saline over 2 h, and group 2 received 30 mmol potassium phosphate in 100 ml salineover 4 h. Patients with severe hypophosphatemia (<0.40 mmol/l; n=10) were also randomized into two groups: group 3 received 45 mmol potassium phosphate intravenously in 100 ml saline over 3 h, and group 4 received 45 mmol potassium phosphate in 100 ml saline over 6 h. Electrolytes, blood gas, renal function were monitored until day 3; urine was collected during and until 6 h after infusions. The overall efficacy of the protocols was 98% by the end of the infusion. There was no statistical difference in phosphate values between groups at the end of infusion or at 24 h. No adverse events were noted; one patient had an increase in serum potassium to 6.1 mmol/l. Phosphaturia in all groups was elevated as evidenced by fractional excretion above 20%. CONCLUSIONS: More rapid administration of large potassium phosphate boluses is effective and safe for correcting hypophosphatemia in ICU patients with preserved renal function if baseline serum potassium is below 4 mmol/l.
RCT Entities:
OBJECTIVE: To evaluate efficacy and safety of aggressive correction of hypophosphatemia with intravenous potassium phosphate in the ICU. DESIGN AND SETTING: Randomized interventional prospective study in the medical and surgical ICU of a tertiary university hospital. PATIENTS: Critically illpatients with hypophosphatemia between June and November 1998. MEASUREMENTS AND RESULTS:Patients with moderate hypophosphatemia (<0.65 and >0.40 mmol/l; n=37) were randomized into two groups: group 1 received 30 mmol potassium phosphate intravenously in 50 ml saline over 2 h, and group 2 received 30 mmol potassium phosphate in 100 ml saline over 4 h. Patients with severe hypophosphatemia (<0.40 mmol/l; n=10) were also randomized into two groups: group 3 received 45 mmol potassium phosphate intravenously in 100 ml saline over 3 h, and group 4 received 45 mmol potassium phosphate in 100 ml saline over 6 h. Electrolytes, blood gas, renal function were monitored until day 3; urine was collected during and until 6 h after infusions. The overall efficacy of the protocols was 98% by the end of the infusion. There was no statistical difference in phosphate values between groups at the end of infusion or at 24 h. No adverse events were noted; one patient had an increase in serum potassium to 6.1 mmol/l. Phosphaturia in all groups was elevated as evidenced by fractional excretion above 20%. CONCLUSIONS: More rapid administration of large potassium phosphate boluses is effective and safe for correcting hypophosphatemia in ICU patients with preserved renal function if baseline serum potassium is below 4 mmol/l.
Authors: Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2004-06-15 Impact factor: 17.440
Authors: Anne Loudenot; Charlotte Michot; Corinne Alberti; Priscilla Armoogum; Michael Tsapis; Stéphane Dauger Journal: Intensive Care Med Date: 2010-05-12 Impact factor: 17.440
Authors: Regina Goetz; Yuji Nakada; Ming Chang Hu; Hiroshi Kurosu; Lei Wang; Teruyo Nakatani; Mingjun Shi; Anna V Eliseenkova; Mohammed S Razzaque; Orson W Moe; Makoto Kuro-o; Moosa Mohammadi Journal: Proc Natl Acad Sci U S A Date: 2009-12-04 Impact factor: 11.205
Authors: Daniël A Geerse; Alexander J Bindels; Michael A Kuiper; Arnout N Roos; Peter E Spronk; Marcus J Schultz Journal: Crit Care Date: 2010-08-03 Impact factor: 9.097